[A21-80] Berotralstat (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2021
Project no.:
A21-80
Commission:
Commission awarded on 08.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.